Cargando…

Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study

BACKGROUND: Patients with type 2 diabetes mellitus and advanced kidney disease are usually treated with insulin. However, the prolonged pharmacokinetic insulin profile in patients with delayed renal insulin elimination impairs a successful therapy. Due to its hepatic metabolism, pioglitazone is a po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galle, Jan, Kleophas, Werner, Dellanna, Frank, Schmid, Volkmar H.R., Forkel, Claudia, Dikta, Gerhard, Krajewski, Vera, Fuchs, Winfried, Forst, Thomas, Pfützner, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383235/ https://www.ncbi.nlm.nih.gov/pubmed/22739963 http://dx.doi.org/10.1159/000337334

Ejemplares similares

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
por: Pfützner, Andreas, et al.
Publicado: (2011)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
por: Pfützner, Andreas, et al.
Publicado: (2007)

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
por: Forst, Thomas, et al.
Publicado: (2012)

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes
por: Forst, T, et al.
Publicado: (2010)

ODP426 SPIOMET4HEALTH: a 4-Arm Trial to Test the Effects of Lifestyle Intervention plus either Placebo, or Pioglitazone (PIO), or Spironolactone-Pioglitazone (SPIO), or Spironolactone-Pioglitazone-Metformin (SPIOMET) in Adolescent Girls and Young Women with PCOS
por: Ibanez, Lourdes, et al.
Publicado: (2022)

Pioglitazone: Indian perspective
por: Shukla, Rishi, et al.
Publicado: (2011)

A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
por: Dupuis, Luc, et al.
Publicado: (2012)

Role of C-Peptide in the Regulation of Microvascular Blood Flow
por: Forst, T., et al.
Publicado: (2008)

Improvements in six aspects of quality of care of incident hemodialysis patients – a real-world experience
por: Drozdz, Maciej, et al.
Publicado: (2021)

Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2022)

Pioglitazone-Induced Acute Rhabdomyolysis
por: Slim, Raoudha, et al.
Publicado: (2009)

Investigation of the antibacterial activity of pioglitazone
por: Masadeh, Majed M, et al.
Publicado: (2011)

Usage of pioglitazone at Medanta, the Medicity
por: Mithal, Ambrish, et al.
Publicado: (2014)

Pioglitazone: A prudent prescription
por: Kalra, Sanjay, et al.
Publicado: (2013)

Reassessment of Pioglitazone for Alzheimer’s Disease
por: Saunders, Ann M., et al.
Publicado: (2021)

Is future given ?
por: Prigogine, Ilya
Publicado: (2003)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes
por: Forst, Thomas, et al.
Publicado: (2010)

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)
por: Singh, Surjit, et al.
Publicado: (2016)

Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis
por: Luedike, Peter, et al.
Publicado: (2015)

C-Peptide and Its C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients
por: Hach, Thomas, et al.
Publicado: (2008)

Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis
por: Li, Shen, et al.
Publicado: (2018)

Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis
por: Drozdz, Maciej, et al.
Publicado: (2019)

Evaluation of Acute Toxicity of Pioglitazone in Mice
por: Chinnam, Pushpalatha, et al.
Publicado: (2012)

Pioglitazone, bladder cancer, and detection bias
por: Dolin, Paul
Publicado: (2014)

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

Pioglitazone: A review of analytical methods
por: Satheeshkumar, N., et al.
Publicado: (2014)

Influence of trazodone on the pharmacodynamics and pharmacokinetics of pioglitazone
por: Pradeepkumar, Bhupalam, et al.
Publicado: (2022)

Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective
por: Kanhai, Anish A., et al.
Publicado: (2020)

Not to Be Given during Pregnancy
por: Hugenin,
Publicado: (1895)

Simultaneous Estimation of Metformin and Pioglitazone by Ultraviolet Spectrophotometry
por: Goswami, Laxmi, et al.
Publicado: (2010)

Preparation and Characterization of Pioglitazone Cyclodextrin Inclusion Complexes
por: Pandit, V, et al.
Publicado: (2011)

Pioglitazone in Clinical Practice: Where Are We Now?
por: Govindan, Joytish, et al.
Publicado: (2012)

The Effect of Pioglitazone on Pharmacokinetics of Carbamazepine in Healthy Rabbits
por: Abushammala, Issam
Publicado: (2015)

Toxicological evaluation of subchronic use of pioglitazone in mice
por: Elshama, Said Said, et al.
Publicado: (2016)

Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)

Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘real-world’ comparison from the DOPPS
por: Locatelli, Francesco, et al.
Publicado: (2018)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Elevated Peripheral Visfatin Levels in Narcoleptic Patients
por: Dahmen, Norbert, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_69s5lfcr14dlgafpg68drt00s0